(NASDAQ: SPRY) Ars Pharmaceuticals's forecast annual revenue growth rate of 31.21% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.28%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.62%.
Ars Pharmaceuticals's revenue in 2025 is $142,772,000.On average, 8 Wall Street analysts forecast SPRY's revenue for 2025 to be $8,226,379,105, with the lowest SPRY revenue forecast at $7,555,987,825, and the highest SPRY revenue forecast at $8,837,856,612. On average, 8 Wall Street analysts forecast SPRY's revenue for 2026 to be $18,475,793,882, with the lowest SPRY revenue forecast at $14,627,617,456, and the highest SPRY revenue forecast at $24,491,720,347.
In 2027, SPRY is forecast to generate $32,508,342,700 in revenue, with the lowest revenue forecast at $24,217,909,695 and the highest revenue forecast at $45,662,127,365.